Retinal neovascularization is a leading cause of blindness.While current anti-VEGF drugs effectively inhibit pathological angiogenesis,some patients develop resistance or reduced responsiveness to treatments over time...Retinal neovascularization is a leading cause of blindness.While current anti-VEGF drugs effectively inhibit pathological angiogenesis,some patients develop resistance or reduced responsiveness to treatments over time,leading to diminished effectiveness.In this study,we identified high activation of the cGAS-STING signaling pathway,which exacerbated pathological neovascularization and vessel leakage.We developed an injectable thermo-responsive supramolecular hydrogel loaded with an anti-STING drug.The hydrogel,made of Pluronic F127 demonstrated excellent transparency and biocompatibility.Importantly,the thermo-sensitive property allowed for precise spatial release of the drug,extending the effective treatment duration of C-176,which suppressed STING activation in the retina,reduced inflammation and protected retinal tissue.Hydro^(C-176) effectively inhibited microglial cell infiltration and the release of inflammatory angiogenic factors,highlighting its enhanced efficacy.While demonstrating slightly lower effectiveness compared to traditional anti-VEGF therapy,Hydro^(C-176) exhibited more robust capabilities in regulating ocular microenvironmental inflammation.This approach may assist in enhancing the sensitivity and effectiveness of anti-VEGF therapy for reducing ocular inflammation,potentially improving patients’response to traditional treatment.These results have suggested innovative and comprehensive strategies for the management of retinal neovascularization.展开更多
基金This study was supported by grants from the National Natural Science Foundation of China(No.82271054,ZL,No.U20A20363,JH).
文摘Retinal neovascularization is a leading cause of blindness.While current anti-VEGF drugs effectively inhibit pathological angiogenesis,some patients develop resistance or reduced responsiveness to treatments over time,leading to diminished effectiveness.In this study,we identified high activation of the cGAS-STING signaling pathway,which exacerbated pathological neovascularization and vessel leakage.We developed an injectable thermo-responsive supramolecular hydrogel loaded with an anti-STING drug.The hydrogel,made of Pluronic F127 demonstrated excellent transparency and biocompatibility.Importantly,the thermo-sensitive property allowed for precise spatial release of the drug,extending the effective treatment duration of C-176,which suppressed STING activation in the retina,reduced inflammation and protected retinal tissue.Hydro^(C-176) effectively inhibited microglial cell infiltration and the release of inflammatory angiogenic factors,highlighting its enhanced efficacy.While demonstrating slightly lower effectiveness compared to traditional anti-VEGF therapy,Hydro^(C-176) exhibited more robust capabilities in regulating ocular microenvironmental inflammation.This approach may assist in enhancing the sensitivity and effectiveness of anti-VEGF therapy for reducing ocular inflammation,potentially improving patients’response to traditional treatment.These results have suggested innovative and comprehensive strategies for the management of retinal neovascularization.
